Depression and Anxiety Trial, Recruiting NCT07242105 Sponsor: Stanford University Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT07242105
Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Men and women between the ages of 18 and 65.
  • People who have been diagnosed with major depressive disorder, confirmed through a structured clinical interview.
  • People who are currently experiencing a depressive episode, confirmed through a structured clinical interview.
  • People with moderate-to-severe depression, based on a score between 11 and 20 on a standardised depression symptom questionnaire called the QIDS.
  • People with a good enough understanding of English to follow EEG and TMS instructions and complete clinical questionnaires.
  • People with no current or past neurological conditions.
  • People with no seizure disorder and no known risk of seizures.
  • A separate group that may also be considered: men and women aged 18 to 65 who have epilepsy that has not responded to medication and who are admitted to hospital for a specific type of brain monitoring procedure — these individuals must be able to understand and agree to the study consent process.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who cannot have an MRI scan, for example due to having metal implants in the body.
  • People with a history of head injury that involved loss of consciousness.
  • People with a history of seizures, or who are taking medications known to lower the seizure threshold (such as olanzapine, chlorpromazine, or lithium).
  • People with a neurological condition or a medical condition that is not well controlled.
  • People with any unstable medical condition.
  • People who are currently misusing substances such as drugs or alcohol.
  • People who have been diagnosed with a psychotic disorder or bipolar disorder.
  • People who have previously tried electroconvulsive therapy (ECT) without it being effective.
  • People who have attempted suicide within the past year.
  • People who are currently pregnant or breastfeeding.
  • People who have received repetitive transcranial magnetic stimulation (rTMS) treatment within the past six months.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

If you need support right now

This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.

If you or someone else is in immediate danger, call 000.

  • Lifeline — 24/7 crisis support: 13 11 14
  • Suicide Call Back Service — 24/7 counselling: 1300 659 467
  • 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
  • Beyond Blue — 24/7 mental health support: 1300 22 4636
  • Emergency: 000

Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.

Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.

Contact this trial

Principal Investigator: Corey J Keller, MD, PhD, Stanford University

Phone: 408-840-3313

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
23 October 2025
Est. completion
30 August 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Changes in Anterior EL-TEP Amplitude after single-pulse TMS (spTMS); Changes in Posterior EL-TEP Amplitude after spTMS; Changes in intracranial TMS-Evoked Potential (iTEP) Amplitude after TMS-iEEG

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov